Testoviron Depot Adverse Reactions

The most commonly reported adverse reactions with Testoviron Depot are injection site pain, injection site erythema, and cough and/or dyspnoea during or immediately after the injection.
Injections of oily solutions such as Testoviron Depot have been associated with systemic reactions: cough, dyspnoea and chest pain. There may be other signs and symptoms including vasovagal reactions such as malaise, hyperhydrosis, dizziness, paraesthesia or syncope.
High-dosed or long-term administration of testosterone, including Testoviron Depot, increases the tendency to water retention and oedema.
Spermatogenesis is inhibited by long-term and high-dosed treatment with Testoviron Depot.
If, in individual cases, frequent or persistent erections occur, the dose should be reduced or the treatment discontinued in order to avoid injury to the penis.
Various skin reactions including injection site reactions (injection site pain, injection site erythema, injection site induration, injection site swelling, injection site inflammation) may occur.
Other events reported with Testoviron Depot include benign and malignant liver tumours, polycythaemia, hypersensitivity reactions, weight increase, liver function test abnormalities, jaundice, acne, alopecia, rash, urticaria, pruritus, Prostatic Specific Antigen (PSA) increase, libido increase, libido decrease gynaecomastia and post marketing reports of venous thromboembolism.
As with other testosterone-containing products, the use of Testoviron Depot may commonly cause an increase in haematocrit, red blood cell count or haemoglobin.
Hostility/aggression and increased hair growth have been reported under treatment with testosterone-containing preparations. Regarding adverse effects associated with the use of androgens, also refer to Precautions.
Reporting Suspected Adverse Effects: Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.